Health
Animal data supports efficacy of baricitinib vs SARS-COV-2 – News-Medical.Net
The high burden of disease caused by the COVID-19 pandemic has led to much research on effective ways to mitigate the health, social, and economic impact of the spread of the infection. A recent study published on the preprint server bioRxiv* in September 202…
The high burden of disease caused by the COVID-19 pandemic has led to much research on effective ways to mitigate the health, social, and economic impact of the spread of the infection. A recent study published on the preprint server bioRxiv* in September 2020 reports on the characteristics of the drug baricitinib when used as monotherapy to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Inflammatory Responses in COVID-19
Severe COVID-19 is associated with high fever, non-…
-
Noosa News24 hours agoTerrifying break-in at childcare centre on Sunshine Coast ends with death of man
-
Noosa News21 hours agoADF to introduce billion-dollar drone dome over Brisbane 2032
-
General19 hours agoQueensland government strikes new deal with Bravus to defer royalties, expand Carmichael coal mine
-
Business24 hours agoEverything you need to know about the BHP dividend